First Line B plus R in Elderly Patients with Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma: A Real- World Experience

被引：0
|
作者：
Kotchetkov, Rouslan [1 ]
Susman, David [2 ]
Gerard, Lauren M. [3 ]
Dimaria, Erica [4 ]
Nay, Derek [5 ]
Prica, Anca [6 ]
机构：
[1] Univ Toronto, Med, Toronto, ON, Canada
[2] Univ Western Ontario, Med, London, ON, Canada
[3] Royal Victoria Hosp, Med Oncol, Barrie, ON, Canada
[4] Royal Victoria Hlth Ctr, Med Oncol, Barrie, ON, Canada
[5] Royal Victoria Hosp, Barrie, ON, Canada
[6] Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-144888
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4519
引用
收藏
页数：5
相关论文
共 50 条
  • [1] First-line treatment with Bendamustine plus Rituximab for patients with indolent non-Hodgkin's lymphoma or Mantle cell lymphoma: Real-world experience.
    Kotchetkov, Rouslan
    Susman, David
    Gerard, Lauren
    DiMaria, Erica
    Nay, Derek Wayne
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] EFFICACY AND SAFETY OF BENDAMUSTINE IN ASSOCIATION WITH RITUXIMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH INDOLENT NON-HODGKIN LYMPHOMA OR MANTLE CELL LYMPHOMA
    Cencini, E.
    Fabbri, A.
    Iannuzzi, A.
    Schiattone, L.
    Brambilla, C. Zuanelli
    Bocchia, M.
    HAEMATOLOGICA, 2017, 102 : 112 - 112
  • [3] Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
    O'Connor, OA
    Wright, J
    Moskowitz, C
    Muzzy, J
    MacGregor-Cortelli, B
    Stubblefield, M
    Straus, D
    Portlock, C
    Hamlin, P
    Choi, E
    Dumetrescu, O
    Esseltine, D
    Trehu, E
    Adams, J
    Schenkein, D
    Zelenetz, AD
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) : 676 - 684
  • [4] Phase II trial of bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or elderly mantle cell lymphoma in Japan.
    Ishizawa, Kenichi
    Ogura, Michinori
    Maruyama, Dai
    Abe, Yasunobu
    Ando, Kiyoshi
    Izutsu, Koji
    Terui, Yasuhito
    Yoshitaka, Imaizumi
    Fukuhara, Noriko
    Uchida, Toshiki
    Choi, Ilseung
    Ohmachi, Ken
    Yamamoto, Go
    Tobinai, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice
    Becker, M.
    Tschechne, B.
    Reeb, M.
    Schwinger, U.
    Bruch, H. -R.
    Frank, M.
    Strassl, L.
    ANNALS OF HEMATOLOGY, 2015, 94 (09) : 1553 - 1558
  • [6] Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice
    M. Becker
    B. Tschechne
    M. Reeb
    U. Schwinger
    H.-R. Bruch
    M. Frank
    L. Straßl
    Annals of Hematology, 2015, 94 : 1553 - 1558
  • [7] Bendamustine A Review of its Use in the Management of Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
    Garnock-Jones, Karly P.
    DRUGS, 2010, 70 (13) : 1703 - 1718
  • [8] BendamustineA Review of its Use in the Management of Indolent Non-Hodgkin’s Lymphoma and Mantle Cell Lymphoma
    Karly P. Garnock-Jones
    Drugs, 2010, 70 : 1703 - 1718
  • [9] First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma
    Hainsworth, JD
    SEMINARS IN ONCOLOGY, 2003, 30 (01) : 9 - 15
  • [10] Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma
    Hainsworth, JD
    Litchy, S
    Burris, HA
    Scullin, DC
    Corso, SW
    Yardley, DA
    Morrissey, L
    Greco, FA
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (20) : 4261 - 4267
12345